Article
Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Pathology, research and practice - 1 Jun 2018
Kim Hyun Sik, Kwon Mi Jung, Song Joon Ho, Kim Eun Soo, Kim Ho Young, Min Kyueng-Whan
Abstract excerpt
IDH mutation and MGMT promoter methylation are reliable prognostic and predictive biomarkers in grade II-IV diffuse gliomas. Recurrent mutations in the promoter region of the telomerase reverse transcriptase (TERTp) gene have also been found in diffuse gliomas. However, the prognostic and predictive effects of TERTp mutation on IDH or MGMT status are largely unknown. IDH1/2 and TERTp mutations, as well as MGMT...
Topics
Join the communities discussing this publication.